Regulation of pro-protein convertase subtilisin/kexin type 9 (PCSK9) by drugs has led to the
development of a still small number of agents with powerful activity on low-density …

While the impact of very low concentrations of low–density lipoprotein cholesterol (LDL-C)
on cardiovascular prevention is very reassuring, it is intriguing to know what effect these …

Background It is well known that dyslipidemia and chronic hyperglycemia increase the onset
of diabetes and diabetic complication. The aim of this study is to see the association of trace …

PCSK9 plays a critical role in cholesterol metabolism via the PCSK9–LDLR axis. Liver-
derived, circulating PCSK9 has become a novel drug target in lipid-lowering therapy …

Aim: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been identified as an
important regulator of low-density lipoprotein (LDL) receptor processing. Evolocumab and …

Background Proprotein convertase subtilisin/kexin type 9 (PCSK9), a major regulator of
cholesterol homeostasis, is associated with glucose metabolism. Liraglutide, a glucagon-like …

Background Proprotein subtilisin kexin type 9 (PCSK9) and lipoprotein (a)[Lp (a)] levels are
causative risk factors for coronary heart disease. Objectives The objective of the study was to …

Low-density lipoprotein cholesterol (LDL-C) is a major cardiovascular risk factor, but other
lipid variables such as triglycerides (TRGs), high-density lipoprotein cholesterol (HDL-C) …

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) exerts an important role
in inflammatory processes, lipids homeostasis, and cardiometabolic disorders that are …

The adipocytokine adiponectin and its structural homologs, the C1q/TNF-related proteins
(CTRPs), increase insulin sensitivity, fatty acid oxidation and mitochondrial biogenesis …